Six Executives Promoted Based on Performance

On July 2, Hanmi Group announced that it had promoted six executives who have delivered innovative results in their respective divisions.


This regular round of executive promotions for the second half of the year is the first since the group adopted a professional management system. Three executives were promoted at the group’s holding company, Hanmi Science, and another three at the operating company, Hanmi Pharmaceutical.

Vice President Nayoung Kim, Head of Innovation Growth Division at Hanmi Pharmaceutical (left), and Vice President Inyoung Choi, Head of Future Growth Division at Hanmi Pharmaceutical (right). Hanmi Pharmaceutical

Vice President Nayoung Kim, Head of Innovation Growth Division at Hanmi Pharmaceutical (left), and Vice President Inyoung Choi, Head of Future Growth Division at Hanmi Pharmaceutical (right). Hanmi Pharmaceutical

View original image

Regarding Hanmi Pharmaceutical, the company explained that this was the first executive appointment by CEO Hwang Sangyeon since taking office earlier this year, reflecting his determination to steer the business toward future and innovation-driven growth.


According to Hanmi Group, this round of promotions was performance-based, focusing on talent who have achieved results in the group’s core areas such as research and development (R&D), global business development (BD), and healthcare business. Hanmi Group has secured growth momentum this year, having gained market recognition for its global technology exports and innovative new drug development capabilities focused on obesity and metabolic diseases.


In this round, Nayoung Kim, previously Executive Director at Hanmi Pharmaceutical, and Inyoung Choi, also previously Executive Director, were both promoted to Vice President. At Hanmi Science, Junseop Shin was promoted to Senior Executive Director, Jiwoong Maeng was promoted to Executive Director, and Junwon Lee was promoted to Deputy Executive Director. In addition, Jaehyuk Choi, Head of Group at Hanmi Pharmaceutical, was promoted to Director.


Nayoung Kim, Vice President at Hanmi Pharmaceutical, played a key role in establishing a systematic commercialization strategy for the "H.O.P (Hanmi Obesity Pipeline)" project, which is the company’s growth strategy for obesity and metabolic diseases, and in strengthening the foundation for market entry.


Vice President Inyoung Choi and Executive Director Jiwoong Maeng have led the development of next-generation innovative drugs and global business achievements, significantly contributing to the enhancement of Hanmi’s R&D capabilities. Their efforts, including large-scale technology exports to global pharmaceutical companies, have further solidified market trust and highlighted the value of Hanmi Pharmaceutical’s proprietary platform technology "Lapscovery," resulting in strong global market performance.


Director Jaehyuk Choi has conducted research and development on the obesity and metabolic disease pipeline at the Future Growth Division’s Obesity and Metabolic Disease Center, participating in the development of core pipelines including the H.O.P project.


Senior Executive Director Junseop Shin at Hanmi Science has driven the growth of the medical device business in the healthcare division, contributing to the expansion of the business portfolio and strengthening organizational competitiveness.


Deputy Executive Director Junwon Lee was included in this round of promotions for his achievements leading the Medical Device Planning Team, where he delivered results in new business planning, product strategy development, and operational efficiency improvements.



A Hanmi Group official stated, "This round of executive appointments was performance-oriented, comprehensively considering performance, expertise, and future growth potential," adding, "We plan to continuously strengthen the group’s core growth engines, such as global new drug development, technology exports, and new healthcare businesses."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing